Targeting the expression of T antigens with selinexor (KPT‐330) shows promise for Merkel cell polyomavirus‐positive Merkel cell carcinoma treatment

Authors:
Publisher website
Google Scholar
Abstract
Merkel cell carcinoma (MCC) is a rare primary neuroendocrine skin cancer. In the Northern hemisphere, the disease most commonly arises as a result of infection with Merkel cell polyomavirus (MCPyV).1 Although the incidence of MCC is only 0.7 per 100,000 individuals in the United States, this number is increasing worldwide, and the cancer is highly aggressive, often carrying a poor prognosis.2 Immunotherapies such as pembrolizumab have emerged as leading treatments for MCPyV‐associated MCC; however, only a subset of patients respond to these agents, and many require other treatments to remain in remission.

This publication has 8 references indexed in Scilit: